Capricorn Therapeutics shares rose 65% after the US Food and Drug Administration agreed to review the latest data on its new Duchenne muscular dystrophy drug.

Zhitongcaijing · 1d ago
Capricorn Therapeutics shares rose 65% after the US Food and Drug Administration agreed to review the latest data on its new Duchenne muscular dystrophy drug.